AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06549868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-based bedtime routine
Description: Dyads in the yoga intervention group receive a picture book outlining a bedtime-themed yoga routine and are instructed to incorporate it into their bedtime routine at least four nights per week for four weeks. The routine guides children through a sequence of yoga poses, starting with the mountain pose and ending in child's pose, designed to calm them as the story progresses. Parents are given a bedtime diary to record the date, whether the child completed the yoga routine each evening, and any comments about their experience with the book.~At week 6, families return to the lab, complete anthropometric assessments and questionnaires, and are fitted with accelerometers to wear for the next week. The accelerometers are returned and data is downloaded a week later. Families are then encouraged to continue using the yoga routine as often as they wish for an additional four weeks, although the frequency of use is not tracked during this maintenance period.
Study NCT02634697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program
Description: 8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
Study NCT02634697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response Resiliency Program
Description: 8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
Study NCT02524899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.
Study NCT02524899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.
Study NCT02524899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
Study NCT02644525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: A single dose of imatinib 200mg PO is given
Study NCT02644525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: A single dose of imatinib 400mg PO is given
Study NCT02644525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: A single dose of imatinib 600mg PO is given
Study NCT02644525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo pill is given
Study NCT05272163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Type
Description: Targets can be specific or categorical
Study NCT05272163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Target Presence
Description: There is or is not a target present on each trial
Study NCT00515164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
Description: 20 mL Hydrogel
Study NCT02162732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Therapy
Description: A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
Study NCT01438229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)
Description: Catheter-based RF ablation in renal artery
Study NCT04265547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Cancer Risk Reduction Household Intervention
Description: This study will focus the intervention on ways at the individual level to reduce sources of Polycyclic Aromatic Hydrocarbons (through cooking methods, exposure to cigarette smoking, indoor air filters) and also individual ways to reduce sources of other Endocrine Disrupting Chemicals. Mother-daughter pairs will partake in an educational session at the baseline visit, covering topics on reading labels, cleaning habits, and cooking methods for reducing exposures. Participants will also be introduced to free resources for consumer product safety information. The intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy measurement, and questionnaire completion. The control arm will be offered the intervention products at this time.
Study NCT00429702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron®
Description: Given IV
Study NCT00429702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decadron®
Description: Given IV
Study NCT00429702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl®
Description: Given IV
Study NCT05272163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Checklist
Description: In fact, there is a checklist on every trial but these results will be compared to a non-checklist condition from another experiment
Study NCT01915849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 15 mg, 50 mg and 150 mg
Study NCT00429702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ativan®
Description: Given IV
Study NCT00429702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron hydrochloride
Description: Given IV
Study NCT00429702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron hydrochloride
Description: Given IV
Study NCT02424461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: 1 injection 1 g per day for 2 days
Study NCT02424461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacine
Description: 400 mg/jour (200 mg/ jour in case of renal failure) for seven days
Study NCT02424461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacine
Description: 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
Study NCT02424461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of ofloxacine
Description: Placebo of ofloxacine for 7 days
Study NCT03377075 — intervention group
Intervention type: DEVICE
Intervention: AL measurement
Description: IOL Master 500 (Carl Zeiss AG, Germany)
Study NCT03377075 — intervention group
Intervention type: DEVICE
Intervention: OCT
Description: Choroidal and retinal thickness measurement (DRI OCT-1 Model Triton (plus), Topcon, Tokyo, Japan)
Study NCT04055896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reduction
Description: Systematic approach to reduction in polypharmacy
Study NCT02181205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Study NCT02181205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02859597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula at 50 liters per minute and 50% oxygen will initially be used for oxygenation.
Study NCT02859597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula
Description: Control group will receive oxygen via standard flow nasal cannula at 5 liters per minute (approximately an FiO2 of 0.35)
Study NCT01253980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days
Study NCT01253980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.~Dose 20-30mg/kg 8 hourly for 5 days
Study NCT00447915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronic acid 0.5mg
Description: 0.5mg(i.v.)/month for 35 months
Study NCT00447915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIS placebo
Description: 0 mg(p.o.)/day for 36 months
Study NCT00447915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0mg ibandronic acid
Description: 1.0mg(i.v.)/month for 35 months
Study NCT00447915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronic acid placebo
Description: 0mg(i.v.)/month for 35 months
Study NCT00447915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5mg RIS
Description: 2.5 mg(p.o.)/day for 36 months
Study NCT00447915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamine D3
Description: Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
Study NCT02524899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
Study NCT02124005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT00447915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Vitamine D3
Description: Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
Study NCT01915849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02280681 — intervention group
Intervention type: OTHER
Intervention: No intervention, only questionnaire
Description: No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
Study NCT03819244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 940 nm Gallium Aluminum Arsenide Diode Laser
Description: Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with diode laser for placing the healing abutment.
Study NCT03819244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2780 nm Er,Cr:YSGG Laser
Description: Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
Study NCT01489787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:~* One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.~* One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient.
Study NCT02336633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
Study NCT02336633 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00999687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo Naturalis Extract in Oil
Description: Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
Study NCT00999687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indigo Naturalis Extract in Oil
Description: Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
Study NCT00999687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
Study NCT01126606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacid Silver (Lactic acid)
Description: Liquid soap, daily use
Study NCT01126606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerine Vegetal Soap Granado Traditional
Description: Vegetal soap, daily use
Study NCT01717040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
Study NCT01717040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
Study NCT03673592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PGT-A
Description: PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
Study NCT02007447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCYTOCINA - SPRAY NASAL
Description: The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
Study NCT02007447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OCYTOCINA - SPRAY NASAL
Description: The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
Study NCT03746444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: The patients in general anesthesia group will undergo general anesthesia
Study NCT03746444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: The patients in Group R will be given combined spinoepidural anesthesia
Study NCT01899209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STARR
Study NCT01899209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Ventral Rectopexy
Study NCT01253915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Description: 10 sec/nostril up to 4 times to treat one migraine
Study NCT01253915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 sec/nostril up to 4 times to treat a migraine
Study NCT01101906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: OSI-906 administered orally
Study NCT01101906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally
Study NCT02057380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral
Study NCT01489787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
Study NCT01489787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.~Several metastases can be treated in the same patient
Study NCT04370028 — intervention group
Intervention type: DRUG
Intervention: Divaza
Description: Oral administration.
Study NCT02776280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal
Description: Typical Brazilian meal consisting of rice, beans and meat with vegetables
Study NCT02776280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Meal
Description: Typical Brazilian meal consisting of rice, beans and meat with vegetables
Study NCT01108809 — intervention group
Intervention type: DRUG
Intervention: Telmisartan or Telmisartan and Hydrochlorthiazide
Description: Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
Study NCT02057380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: oral
Study NCT02057380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous (IV) infusion
Study NCT00400491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D)
Description: Cholecalciferol capsule 20.000 IU twice per week for 6 months
Study NCT00400491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule twice a week, identical to the cholecalciferol capsules
Study NCT03334578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrografin
Description: Gastrografin group
Study NCT03435653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OFD with DFDBA
Description: Control Group Open flap debridement with DFDBA Periodontal surgery will be performed in the form of open flap debridement along with placement of demineralized freeze dried bone allograft at the defect site.
Study NCT03435653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OFD with decortication and DFDBA
Description: Test Group Open flap debridement with decortication and demineralised freeze dried bone allograft Open flap debridement with decortication and placement of demineralized freeze dried bone allograft at the defect site.
Study NCT03175380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bacillus Calmette-Guérin
Description: BCG injection for prevention of tuberculosis
Study NCT03319992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)
Description: RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
Study NCT00002706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Description: Undergo vaginal hysterectomy and BSO via laparoscopy
Study NCT00002706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00002706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00002706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo total abdominal hysterectomy and BSO via conventional laparotomy
Study NCT02892851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nuclei (STN-DBS)
Description: 3 phases :~* Parameter setting~* Cross-over double-bind (ON/OFF)~* Open Phase (ON)